C7R-GD2 CAR-T cells for osteosarcoma or neuroblastoma
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma or osteosarcoma that has not improved after standard treatment or has come back.
- You are at least 1 year old.
- You are mostly up and about (performance score 50% or higher for treatment).
- Your liver and kidney function are within a certain range (blood tests will be checked).
- You cannot have active autoimmune disease, brain tumors or metastases, or allergies to mouse proteins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This trial is testing a new type of immunotherapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to see if these specially engineered cells can find and destroy the cancer cells.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
This trial tests a new CAR-T cell treatment called IM83 for people with osteosarcoma in their arms or legs that has come back or not responded to standard chemotherapy. The goal is to see if it can help when other treatments have stopped working.
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Hear when a new Relapsed Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.